Ana içeriğe atlaAna içeriğe atla
info@smcsalud.org
Kanıt ve araştırma

Kübalı tıbbi programların arkasındaki klinik kanıtlar

Servicios Médicos Cubanos aracılığıyla koordine edilen tedavi programlarının temelini oluşturan etkililik verilerine, sonuçlara ve araştırmalara genel bir bakış. Bireysel sonuçlar değişir ve kişiselleştirilmiş değerlendirme sırasında teyit edilir.

Medically reviewed by Office of Medical Affairs
Reviewed August 5, 2026Last updated August 5, 2026
5,000+

Lung cancer patients treated with CIMAvax-EGF

26+

Countries where Heberprot-P is registered

Millions

Eye surgeries via Operation Miracle

35+

Years of neurorehabilitation at CIREN

Clinical Evidence

Therapy-specific outcomes & trial data

NeuralCIM®

Alzheimer's Disease

54%

showed cognitive improvement at 1 year

In the ATHENEA trial (170 patients), over half of treated patients improved versus 85% disease progression in the placebo group. NeuralCIM is a brain tissue-derived therapy used within Cuba's comprehensive neurological rehabilitation programs.

Source: ATHENEA clinical trial

Heberprot-P®

Diabetic Foot Ulcers

85%+

healing in complex cases

Intralesional recombinant human epidermal growth factor (EGF), developed by Cuba's Center for Genetic Engineering and Biotechnology (CIGB), has helped prevent amputation in thousands of patients across 20+ countries since 2007.

Source: CIGB — Center for Genetic Engineering and Biotechnology

CIMAvax-EGF® & VAXIRA®

Lung Cancer

Multi-center

immunotherapy studies

Therapeutic vaccines developed by Cuba's Center of Molecular Immunology (CIM), studied as maintenance therapy in non-small cell lung cancer. CIMAvax-EGF targets epidermal growth factor; VAXIRA (racotumomab) induces an immune response against N-ganglioside NeuGcGM3.

Source: CIM — Center of Molecular Immunology

Research Institutions

Cuba's medical research ecosystem

The institutions behind Cuba's breakthrough therapies — from biotech research to clinical application.

Center of Molecular Immunology (CIM)

Havana

Therapeutic cancer vaccines & monoclonal antibodies

Developer of CIMAvax-EGF and Vaxira®. A flagship of Cuban biotech with 30+ years of R&D in immunotherapy and oncology.

International Center for Neurological Restoration (CIREN)

Havana

Multidisciplinary neurorehabilitation

Founded in 1989, CIREN treats thousands of international patients with intensive 4–8 week neurorehabilitation programs.

Center for Genetic Engineering and Biotechnology (CIGB)

Havana

Recombinant proteins & growth factors

Developer of Heberprot-P® (recombinant human EGF) for diabetic foot ulcers, registered in 26+ countries worldwide.

Operation Miracle (Operación Milagro)

Nationwide

Large-scale ophthalmology program

A Cuba–Venezuela initiative providing millions of cataract and eye surgeries, with comprehensive pre- and post-operative care.

BioCubaFarma

Havana

Biopharmaceutical enterprise group

Umbrella organization for Cuba's biotech sector, coordinating research, clinical trials, and production across 30+ enterprises.

Kaynaklar

Seçilmiş klinik kaynaklar ve kurumlar

Klinik programlarımız hakemli araştırmaya dayanır ve Küba'nın biyoteknoloji kurumlarıyla koordine edilir — Genetik Mühendisliği ve Biyoteknoloji Merkezi (CIGB) ve Moleküler İmmünoloji Merkezi (CIM) dahil. Hastaların ve kendi hekimlerinin birincil kaynaklara başvurmalarını öneririz:

Gösterilen sonuçlar yayımlanmış klinik verileri ve toplu sonuçları yansıtır. Bireysel sonuçlar tanıya, hastalık aşamasına ve genel sağlığa göre değişir ve La Pradera Uluslararası Sağlık Merkezi'nde kişiselleştirilmiş bir tıbbi değerlendirme sırasında doğrulanır. Bu sayfa eğitim amaçlıdır ve profesyonel tıbbi tavsiye yerine geçmez.

Questions & Answers

Frequently asked questions

Next steps

Learn how these innovations are applied within our clinical programs, or request a personalized consultation with our medical team.